一名慢性髓性白血病患者在接受甲磺酸伊马替尼治疗期间发生浆细胞白血病。

Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate.

作者信息

Maral Senem, Bakanay Sule Mine, Yikilmaz Aysun Senturk, Dilek Imdat

机构信息

Department of Hematology, Ankara Ataturk Training and Research Hospital, Ankara, Turkey.

Department of Hematology, Yildirim Beyazit University, Ankara, Turkey.

出版信息

J Cancer Res Ther. 2018 Oct-Dec;14(6):1431-1433. doi: 10.4103/0973-1482.192762.

DOI:10.4103/0973-1482.192762

PMID:30488870

Abstract

Plasma cell leukemia (PCL) is a rare and an aggressive form of plasma cell dyscrasias. We report a 67-year-old male with PCL which developed while on imatinib mesylate (IM) therapy 38 months after diagnosis of chronic myeloid leukemia (CML). The patient has been treated successfully with bortezomib, melphalan and prednisolone. To our knowledge, only one case of PCL superimposed on Philadelphia positive CML has been reported in the literature and this was before the IM era.

摘要

浆细胞白血病（PCL）是一种罕见且侵袭性的浆细胞发育异常形式。我们报告一例67岁男性浆细胞白血病患者，该患者在慢性髓性白血病（CML）诊断38个月后接受甲磺酸伊马替尼（IM）治疗期间发病。该患者已成功接受硼替佐米、美法仑和泼尼松龙治疗。据我们所知，文献中仅报道过1例费城染色体阳性慢性髓性白血病合并浆细胞白血病的病例，且该病例发生在伊马替尼时代之前。